Sanofi Says Mylan Infringing 18 Insulin Patents

Law360, New York (October 26, 2017, 3:33 PM EDT) -- Sanofi filed a patent infringement suit Tuesday in New Jersey federal court alleging Mylan’s planned generic version of Sanofi’s insulin pen, Lantus, infringes 18 of its patents.

Sanofi said in the complaint that since Mylan informed the company last month that it was seeking U.S. Food and Drug Administration approval to sell generic versions of Sanofi’s Lantus and Lantus SoloSTAR once-a-day insulin medication owned by Sanofi, it has sought a compromise with Mylan but that Mylan has not supplied it with any information.

Mylan has not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.